Healthcare / BiotechnologySão Paulo
$77.44
-2.48 (-3.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.1B · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.9B
P/E
133.9x
↑EV/EBITDA
32.7x
↑ROE
-8.2%
↓Gross Margin
88.2%
↑Debt/Equity
1.26
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.3%
FCF CAGR
+14.0%
FCF margin
26.9%
FCF / Net income
-3.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.27B · net income $-356.1M · FCF $1.15B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.27B | $4.27B | $4.07B | $3.83B | $3.66B |
| Net Income | $-356.1M | $-356.1M | $560.1M | $414.8M | $-224.1M |
| EBITDA | $263.5M | $263.5M | $1.37B | $1.23B | $544.9M |
| EPS | -5.84 | -5.84 | 8.65 | 6.10 | -3.58 |
| Gross Margin | 88.2% | 88.2% | 89.0% | 88.6% | 85.2% |
| Operating Margin | 12.1% | 12.1% | 17.9% | 15.6% | 14.0% |
| Net Margin | -8.3% | -8.3% | 13.8% | 10.8% | -6.1% |
| Balance Sheet | |||||
| Debt/Equity | 1.26 | 1.26 | 1.51 | 1.55 | 1.88 |
| Current Ratio | 2.04 | 2.04 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.15B | $1.15B | $1.35B | $1.05B | $773.8M |
| Returns | |||||
| ROE | -8.2% | -8.2% | 13.7% | 11.1% | -7.3% |
| Valuation | |||||
| P/E | 133.86 | 133.86 | — | — | — |
| EV/EBITDA | 32.65 | 32.65 | — | — | — |
| P/B | 1.06 | 1.06 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 4.9% | 4.9% | 6.1% | 4.8% | — |
| EPS Growth | -167.5% | -167.5% | 41.8% | 270.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.5%
Start / end P/E
n/dx → n/dx
EPS bridge
8.65 → -5.84
Residual
+14.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.